title: Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis.
abstract: There is increasing evidence that neuropeptides such as a substance P, neurotrophins or beta-endorphin, an endogenous agonist for mu-opioid receptor, are involved in the pathogenesis of atopic dermatitis in which mental stress and scratching deteriorate the disease. mu-Opioid receptor, a G-protein-coupled receptor, can be downregulated and internalized by agonists and other factors in vitro. In this study, we investigated the regulation of mu-opioid receptor and nerve endings in atopic dermatitis patients. Skin biopsies from atopic dermatitis patients revealed a significant downregulation of mu-opiate receptor expression in epidermis of atopic dermatitis. Permeabilization of the skin showed that the receptor in keratinocytes from atopic dermatitis is internalized. The mRNA expression pattern of the mu-opiate receptor is different in epidermis taken from patients with chronic atopic dermatitis compared to normal skin. In atopic dermatitis, the mRNA is concentrated in the subcorneal layers of the epidermis and in normal skin in the suprabasal layers. Staining of the nerve endings using protein gene product 9.5 shows a different pattern of epidermal nerve endings in normal skin compared to atopic dermatitis. In normal skin, the epidermal nerve endings are rather thick. However, in atopic dermatitis, the epidermal nerve endings are thin and run straight through the epidermis. Based on these observations and combining the 'intensity' and 'pattern' hypothesis, we propose a new theory especially for histamine-unrelated, peripheral induction of chronic pruritus. We suggest that 'itch' is elicited in the epidermal unmyelinated nerve C-fibers and 'pain' in the dermal unmyelinated nerve fibers. The downregulation of the opioid receptor in the epidermis contributes to the chronic itching. We call this new hypothesis the 'layer hypothesis'.
authors.affiliation: Department of Dermatology, University of Basel, Basel, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Bigliardi-Qi
authors.forename: B
authors.initials: B
authors.lastname: Lipp
authors.forename: L T
authors.initials: LT
authors.lastname: Sumanovski
authors.forename: S A
authors.initials: SA
authors.lastname: Buechner
authors.forename: P L
authors.initials: PL
authors.lastname: Bigliardi
mesh_terms: D001706:Biopsy; D016022:Case-Control Studies; D003876:Dermatitis, Atopic / Q000378:metabolism*; D015536:Down-Regulation; D006801:Humans; D009411:Nerve Endings / Q000378:metabolism* / Q000473:pathology; D016612:Paraffin Embedding; D012333:RNA, Messenger / Q000032:analysis; D017450:Receptors, Opioid, mu / Q000235:genetics / Q000378:metabolism*; D012867:Skin / Q000378:metabolism* / Q000473:pathology
chemical_list: D012333:RNA, Messenger; D017450:Receptors, Opioid, mu